Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE: SYK) announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, introducing Mako Handheld Robotics as an expansion of the Mako family. Mako RPS integrates an intraoperative planner and a robotically enabled saw compatible with Triathlon Total Knee and Q Guidance System.
The system offers active adjustment technology that guides a surgeon's saw to align with the surgical plan and aims to fit into existing workflows without cutting blocks. Stryker will demonstrate Mako SmartRobotics and Mako Handheld Robotics at AAOS 2026, booth #3339.
Stryker (NYSE:SYK) declared a quarterly cash dividend of $0.88 per share, payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026.
The dividend equals the prior quarter and represents a 4.8% increase year-over-year, reflecting steady shareholder distributions.
Stryker (NYSE:SYK) reported strong fourth-quarter and full-year 2025 operating results: Q4 net sales $7.17B (+11.4%), full-year net sales $25.12B (+11.2%), organic growth Q4 +11.0% and FY +10.3%. Adjusted operating margin expanded +100 bps to 30.2% (Q4) and 26.3% (FY). 2026 outlook: organic sales growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10.
Cash flow from operations was $5.04B; acquisitions spending was $4.96B in 2025. Management cites strong capital-product demand and procedural volumes entering 2026.
VB Spine completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France on January 6, 2026, expanding its global manufacturing footprint.
The Cestas site, including its people, infrastructure, and processes, will anchor VB Spine's worldwide manufacturing strategy and support expanded medical education and training programs in Europe. Employees transitioned from Stryker to VB Spine and manufacturing operations continue without interruption. Integration planning is underway to align systems, quality, and supply chain.
Stryker (NYSE:SYK) will report fourth quarter and full year 2025 financial results on Thursday, January 29, 2026. A press release with summary financial information for the period ended December 31, 2025 will be issued at approximately 4:05 p.m. ET and posted to the company's press releases page.
Stryker will host a live webcast at 4:30 p.m. ET on January 29, 2026 to discuss results; the webcast is accessible on the company's Events & Presentations page and an archive will be available about two hours after the call ends.
Stryker (NYSE:SYK) announced a quarterly dividend of $0.88 per share, payable January 30, 2026 to shareholders of record at the close of business on December 31, 2025. The Board said the payout represents a 4.8% increase versus both the prior year and the previous quarter. Management framed the raise as consistent with the company’s capital allocation priorities and confidence in future financial performance.
Stryker (NYSE:SYK) announced Spencer Stiles will become President and Chief Operating Officer effective January 1, 2026. Stiles, a 27-year Stryker veteran and current Group President of Orthopaedics and Spine since 2019, will lead global businesses, strategy, and mergers and acquisitions. Dylan Crotty will be promoted to Group President, Orthopaedics; Crotty has 27 years at Stryker and currently serves as President, Instruments.
The appointments emphasize internal succession, operational continuity, and leadership experience across Orthopaedics, MedSurg, and Neurotechnology.
Stryker (NYSE:SYK) reported third quarter 2025 results: net sales $6.06B (+10.3% reported, +9.6% constant currency) and organic net sales +9.5%. MedSurg & Neurotechnology sales rose 14.4%; Orthopaedics rose 3.9% (pro forma Orthopaedics +12.5% excluding a divestiture). Reported EPS was $2.22 (+2.8%) and adjusted EPS was $3.19 (+11.1%). Adjusted operating margin expanded 90 bps to 25.6%; reported operating margin was 18.7%. Management raised full-year 2025 guidance to organic net sales growth 9.8–10.2% and adjusted EPS of $13.50–$13.60. The results reflect acquisition activity, higher amortization, and increased long-term debt linked to recent transactions.
Stryker (NYSE:SYK) will showcase expanded trauma solutions at the Orthopaedic Trauma Association Annual Meeting, October 15–18, 2025 in Phoenix (booth #601).
The company highlighted extensions to its Pangea and T2 Alpha nailing and plating platforms, including a new T2 Alpha Humeral nail designed for simplicity and streamlined humeral fixation, plus a novel femur reconstruction fracture system that combines T2 Alpha and Pangea for complex native and periprosthetic femur fractures. Stryker emphasizes simplified instrumentation, enhanced stability, and workflow efficiency, and will offer hands-on demonstrations and expert conversations at its booth.
Stryker (NYSE:SYK) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will release its Q3 2025 earnings press release at 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET.
The financial results will cover the quarter ending September 30, 2025. Investors can access the webcast through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.